ProMIS President and CEO, Dr. Elliot Goldstein, stated: “Our latest data lend further support to the potential best in class profile of PMN310. We previously reported greater selectivity and binding of humanized PMN310 for toxic, amyloid beta (A beta) oligomers in direct comparison to other amyloid beta-directed antibodies, including aducanumab.” Aged mice were studied to assess and compare the ability of humanized PMN310 (huPMN310) and aducanumab to cross the blood brain barrier (BBB) and penetrate the CNS.
Read the Full Story at www.nasdaq.com
ProMIS Neurosciences Lead Product Candidate for Alzheimer’s Disease Shows Potential for Improved Therapeutic Potency versus Other Amyloid Beta-Directed Antibodies
More from BusinessMore posts in Business »
- Biogen Stays the Wrong Course After a Key Drug Failure
- What Happened? Alzheon Leaves IPO on the Table for the Second Time | Biospace
- Biogen Inks Two Deals to Make Drugs for Neurological Diseases | NASDAQ
- AC Immune inks $1.7bn deal with Lilly, strategic partnership with WuXi | Outsourcing Pharma
- BioXcel Announces Positive Data On Senile Dementia Of Alzheimer’s Type; Stock Up | NASDAQ